

Edgar Filing: Raptor Pharmaceutical Corp - Form 8-K

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2014, Raptor Pharmaceutical Corp. (the “Company”) issued a press release announcing its financial results for the third quarter and nine months ended September 30, 2014. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Exhibit Description
-------------	---------------------

99.1	Press release issued by Raptor Pharmaceutical Corp. dated November 6, 2014.
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2014 RAPTOR PHARMACEUTICAL CORP.

By: /s/ Frank Lanza

Name: Frank Lanza

Title: Interim Principal Financial and Accounting Officer

Exhibit Index

Exhibit No. Exhibit Description

99.1 Press release issued by Raptor Pharmaceutical Corp. dated November 6, 2014.
